JIR
IRMD icon

James Investment Research’s iRadimed IRMD Stock Holding History

James Investment Research’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Hold
2,454
– – 0.02% 334
2026
Q1 		$236K Hold
2,454
– – 0.03% 319
2025
Q4 		$239K Buy
+2,454
New +$211K 0.03% 324
2023
Q2 		– Sell
-1,754
Closed -$69K – 401
2023
Q1 		$69K Buy
+1,754
New +$63.8K 0.01% 334

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

James Investment Research's IRMD Position: Q2 2026 in Review

James Investment Research held its iRadimed (IRMD) position steady in Q2 2026 at 2,454 shares worth $235K. The position accounts for 0.02% of the portfolio, ranked #334.

James Investment Research first reported a position in IRMD in Q1 2023 and has held it in 4 quarters since. The position peaked at $239K in Q4 2025. 213 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • James Investment Research held 2,454 shares of iRadimed worth $235K as of Q2 2026.
  • James Investment Research left its iRadimed share count unchanged in Q2 2026.
  • iRadimed made up 0.02% of James Investment Research's portfolio in Q2 2026, its #334 holding.
  • James Investment Research first reported a position in iRadimed in Q1 2023 and has held it in 4 quarters since.
  • James Investment Research's iRadimed position peaked at $239K in Q4 2025.
  • 213 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.